Survodutide (BI 456906) is a novel dual agonist targeting both the glucagon and GLP-1 receptors, developed for obesity treatment. Structurally based on glucagon and modified with a C18 fatty diacid for weekly dosing, it stimulates lipolysis and energy expenditure via the glucagon receptor while reducing appetite and gastric emptying through the GLP-1 pathway. In phase 2 trials, survodutide led to greater weight loss than semaglutide, with reductions up to −14.1% over 16 weeks. Doses ≥2.4 mg induced significant bodyweight loss in over 50% of participants, showing sustained results through 46 weeks.
Le Roux, P.C.W., Steen, O., Lucas, K.J., Startseva, E., Unseld, A. and Hennige, A.M. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Survodutide by Stealth Labs, consult with your doctor or healthcare professional.
Le Roux, P.C.W., Steen, O., Lucas, K.J., Startseva, E., Unseld, A. and Hennige, A.M. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology.
Le Roux, P.C.W., Steen, O., Lucas, K.J., Startseva, E., Unseld, A. and Hennige, A.M. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology.
Le Roux, P.C.W., Steen, O., Lucas, K.J., Startseva, E., Unseld, A. and Hennige, A.M. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology.
Home
